Certis oncology announces issuance of u.s. patent for its proprietary certisai predictive oncology intelligence™ platform

San diego--(business wire)-- #certisai--certis oncology solutions, a precision oncology and translational science company, announced today that the united states patent and trademark office (uspto) has allowed a patent application directed to certis's predictive artificial intelligence/machine learning (ai/ml) platform, certisai™. “the patent marks an important milestone for our company,” said peter ellman, president and ceo of certis. “it substantiates the uniqueness of our proprietary platform and the un.
POAI Ratings Summary
POAI Quant Ranking